• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Patients with late stage melanoma remain at risk for further primary melanoma

byAndrew Bishara
December 7, 2013
in Chronic Disease, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD 

1.  Patients diagnosed with stage III or IV melanoma are at risk for the development of further primary melanomas, particularly if they have a history of multiple primary melanomas prior to their diagnosis. 

Evidence rating level: 2 (Good)

Study Rundown: In recent year, B-raf inhibitors such as Vemurafenib have been approved for the management of metastatic melanoma. However, clinical trials of these drugs have shown evidence for possible carcinogenesis or increased tumor progression, such as atypical melanocytic proliferations and new primary melanomas. In order to better understand the effect of these drugs, the authors of this retrospective cohort study examined the background incidence of new primary melanomas in patients diagnosed with late stage melanoma.

After analyzing a total of 7778 patients diagnosed with stage III or IV melanoma, the authors found that they remained at risk for the development of additional primary melanomas. Risk factors included male sex and a history of multiple primary melanomas. The authors also compared these patients to those receiving BRAF inhibitors and found that incidence rates were higher in the latter group.

These results benefit from the cohort design and large study population. However, there are also several limitations on the interpretation of these results. First, this was a retrospective trial. Furthermore, comparing the outcomes from this population with patients receiving BRAF inhibitors involves possible measurement bias, as dermatologic assessment is more frequent in BRAF inhibitor trials.

Click to read the article in JCO

RELATED REPORTS

Same appointment mammogram results may result in less stress for patients being screened for breast cancer

Dulaglutide improves glycemic control for youth with type 2 diabetes

Cinpanemab therapy does not prevent Parkinson’s disease progression

Relevant reading: Increased risk of second primary cancers after a diagnosis of melanoma

In-Depth [retrospective cohort study]: The authors of this study analyzed patients diagnosed with stage III or IV melanoma at Melanoma Institute Australia between 1983 and 2008. Patients who received a BRAF inhibitor were excluded. A total of 4215 patients with stage III and 3563 patients with stage IV were included in the study. The primary outcomes measured were 3 month, 6 month, 1 year and 10 year cumulative incidence of new primary melanoma (NPM) following diagnosis of the stage III or IV disease.

For the stage III patients, the 6 month, 1 year and 10 year cumulative incidence rates of developing an NPM were 1.2% (95% CI, 0.86-1.51), 1.8% (95% CI, 1.44-2.26) and 5.9% (95% CI, 5.08-6.74). For stage IV patients, the 3 month, 6 month and 1 year cumulative incidence rates were 0.2% (95% CI, 0.07-0.36), 0.3% (95% CI, 0.15-0.51) and 0.4% (95% CI, 0.25-0.7). For both populations, male sex and prior history of multiple primary melanomas increased the overall incidence of NPM.

By Monica Parks and Andrew Bishara

More from this author: Rituximab linked with reduced chronic immune disease following stem cell transplantation, High-dose prophylaxis for hemophilia increases costs with minimal benefit, Ambrisentan found ineffective against idiopathic pulmonary fibrosis

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: chemotherapychronic diseasehealthmalignant melanomametastaticoncologyrisk
Previous Post

Longer preoperative treatment of advanced pancreatic cancer may extend survival

Next Post

“Benign obesity” perhaps not so benign

RelatedReports

Breast cancer chemoprevention may reduce mortality in lobular carcinoma-in-situ
Oncology

Same appointment mammogram results may result in less stress for patients being screened for breast cancer

August 15, 2022
Pediatric DKA associated with recent acute care visits
Cardiology

Dulaglutide improves glycemic control for youth with type 2 diabetes

August 15, 2022
Brain lesions on MRI linked with subsequent increased stroke risk
Chronic Disease

Cinpanemab therapy does not prevent Parkinson’s disease progression

August 15, 2022
Characteristic differences between young children and adolescents who die by suicide
Weekly Rewinds

2 Minute Medicine Rewind August 8, 2022

August 15, 2022
Next Post
High BMI linked to reduced risk of endometriosis

“Benign obesity” perhaps not so benign

Gestational weight loss may improve outcomes for obese women

BMI, waist circumference associated with semen quality

The CLARITY trial: Adding clopidogrel to STEMI management [Classics Series]

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Same appointment mammogram results may result in less stress for patients being screened for breast cancer
  • Increased use of pediatric CT poses significant oncogenic risk [Classics Series]
  • Pediatric asthma morbidity is associated with geographic location and social determinants of health
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.